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Abstract  
Objectives: Finland is a high-risk multiple sclerosis (MS) region, but a national MS register has not existed 
until 2014. In this paper we present the Finnish MS register variables and data collected by 31.12.2018.  
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Materials & Methods: Numbers and data counts of MS patients in the register (ICD-10 code G35) are 
presented. The disease types and proportion of patients receiving disease modifying treatments (DMTs) were 
analyzed in five hospital districts with most complete data sets. MS prevalence in Finland was estimated using 
administrative hospital discharge data as an additional resource.  
 
Results: There were a total of 8722 MS patients in the Finnish MS register by 31.12.2018 (71.5 % females). 
Mean age at MS diagnosis was 38.7 years and peak prevalence was at age 50-54 years. Disease course was 
relapsing remitting (RRMS) in 66.7%, secondary progressive (SPMS) in 13.5%, and primary progressive 
(PPMS) in 7.9% of the 5365 MS patients in the selected districts with most complete data. A total of 66.0 % of 
RRMS patients, 19.6% of SPMS patients and 9.9% of PPMS patients were receiving DMTs. By combining MS 
register data with databases of those hospitals that had not joined the register, the nation-wide prevalence 
estimate was between 10 and 11 thousand patients (corresponding to crude prevalence 180-200/100,000). 
 
Conclusions: The Finnish MS register is currently used in 15/21 Finnish hospital districts. By register 
integration into the electronic patient files, the coverage of the register has increased to approximately 80% of 
the estimated Finnish MS population.  
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Introduction 
Finland is a high-risk multiple sclerosis (MS) region based on regional studies (1-3), but nationwide MS 
prevalence studies have not been performed recently. A national MS register was launched in 2014, which 
enables systematic follow-up of incidence and prevalence figures as well as many clinical variables. Disease 
modifying treatments (DMTs) for MS have developed rapidly during the last decade. Therefore structured 
documentation of the complex treatment profiles of individual patients is becoming increasingly important. The 
DMTs are considered more effective when administered early on during the disease course (4). Therefore, 
predictive tools to identify patients with highly active disease, who receive greatest benefit from the most 
effective therapies early on, are needed. Moreover, there is a need for a tool to better assess the efficacy, safety 
and cost - benefit ratio of the emerging new DMTs at the national level.  
 
MS registers attempt to bridge these gaps. They are in active use in many European countries (5), and the need 
to further develop these registers is recognized worldwide (6). Registers assist the clinician as a decision-making 
tool in individualized patient follow-up by providing a graphical presentation of the patient’s entire disease 
history. Registers can provide real-world data on the effectiveness, tolerability and safety of MS drugs (7). The 
Norwegian MS register connects with biobank information, thereby facilitating research on biomarkers for MS 
(8). A prediction tool to predict the individual's risk of conversion to secondary progressive multiple sclerosis 
(SPMS) at the time of MS onset has been recently published based on data derived from one of the most 
successful national MS registers, the Swedish MS register (9). 
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The Finnish MS register is a browser-based quality register for public health care organizations. The software 
service is provided by StellarQ (stellarq.com). The development of the register, the steering committee and the 
core features of the register are described at the register home page (neurorekisteri.fi). By 2018, 15/21 of 
Finland’s public hospital districts including all five university hospitals and ten central hospitals have joined the 
service, and most of them have integrated it into their electronic patient documentation system. Statistics of real-
time aggregated anonymized national level data are available to all hospitals who have joined the register. At the 
moment the register is not covering all MS patients in Finland, but an effort is ongoing to achieve complete 
coverage. The funding of the register is based on licensing fees paid by Finnish hospital districts to the software 
service provider.  
 
The objective of this study is to describe the characteristics and status of launching of the Finnish MS register. 
We illustrate the register core variables and the data collected. We provide a rough estimate of the prevalence of 
MS in Finland, and show patient demographics from five hospital districts with more detailed register data. We 
discuss the challenges and future perspectives of this new national MS register. 
 
Materials and Methods 
The national level data was collected from the real-time aggregated anonymized portal of the MS register. Data 
entries into the register were performed either manually by the treating neurologist or by diagnosis integration 
from the hospital administrative data. In both cases, the validity of the G35 and G37.9 diagnoses was verified by 
chart review. A more detailed analysis of the register data was carried out from five hospital districts: Helsinki 
and Uusimaa, Southwest Finland, Tavastia Proper, Northern Savonia and Central Finland. Rationale for this 
selection was that these five hospital districts have entered the patient data both retrospectively and 
prospectively. Prospective data collection started during 2014-2016. Retrospective disease history data from the 
disease onset for each patient has been filled in manually by the treating neurologists, residents, MS nurses, or 
medical students under supervision of the MS register steering committee members. Data from these five 
hospital districts was collected separately from each hospital’s closed register, anonymized and then pooled for 
statistical analysis.  
 
Following data cleansing was used to derive datasets ready for statistical analysis: partial dates were imputed as 
first day of the month or first day of the year depending on the imputation needs, duplicated records were 
removed, and possible discrepant medication events were corrected to be logical. Mean, standard deviation, and 
frequencies were used to produce patient demographics. 
 
This study was approved by the institutional review boards of all the participating hospitals. According to the 
Finnish law, approval of ethical committee was not required, as the study was based on administrative register 
data and included no contact with patients. Office of Data Protection in Finland and the Ministry of Social 
Affairs and Health have endorsed their statements, that no informed consent is needed for entering the patient 
data into the Finnish MS register, since it is regarded as a part of the hospital’s patient documentation system. 
Each hospital district is a register keeper for their own data. 
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Results 
MS register coverage in the Finnish health care districts 
The Finnish MS register was developed foremost to serve the clinician in the daily practice when evaluating 
treatment choices for an MS patient in the outpatient clinic. Therefore, a strong emphasis was given to the 
graphical design of the user interface. Figure 1 shows the front page of the user interface, where the key 
variables of diagnosis date and disease type, current and past EDSS scores and treatment and relapse histories 
are visualized graphically.   
 
Finland is divided into 21 public health care districts, with very different population sizes. The decentralized 
model of health care has been a challenge to the MS register launching, since the register use is voluntary and 
each hospital has decided individually whether to join the register or not. Figure 2 shows the health care districts 
in Finland and which of them have joined the register by 31.12.2018.  
 
At the national level, there were a total of 8722 MS patients (G35) and 512 patients with unspecified 
demyelinative disease of the central nervous system (G37.9) registered in the MS register by 31.12.2018 (71.5% 
females). Mean and median ages at MS diagnosis were 38.7 and 37.0 years, respectively, and peak prevalence 
was at age 50-54 years. The number of G35 patients obtained from the hospital administrative databases from 
the hospitals not yet joined was 778 (Figure 2, discharge data). The number of patients not registered in the 
hospital districts that are using manual entry of patients (Figure 2, nine districts), were identified from the 
hospital administrative databases. This procedure identified 1400 additional patients. These three data sets in 
combination provide an estimate of MS prevalence in Finland up to 10900 at December 31, 2018. No medical 
record review was performed to the patients identified from the administrative databases, a single entry of 
diagnosis G35 was enough for inclusion, and patients in both in- and outpatient care were included. The number 
of MS patients with reimbursement rights for DMTs of MS (Social Insurance Institution of Finland, insurance 
code 109 for G35) was 9372 at 31.12.2018 (11). Since all patients are not applied for the reimbursement rights 
for the DMTs of  MS, this figure does not capture all of the Finnish MS patients. Those MS patients who 
receive infusion therapies, paid entirely from the hospital budgets, may not be captured based on the 
reimbursement rights. According to our register data, approximately 7% of the patients received one of the 
infusion therapies as a first line therapy.  
 
To provide the structure and comprehensiveness of the data collected by the Finnish MS register, we present the 
register variables and the data counts of each variable included in the register. Table 1 describes the variables, 
how many times the variable has been entered in the register, and which proportion of the patients have the 
information included in their data file.  
 
Demographics and disease characteristics of MS patients in the hospital districts with retrospective and 
prospective data  
At the national level, only 62.9% of patients had their relapses entered into the register (Table 1). Therefore, we 
limited our more detailed analysis into those hospital districts where both retrospective and prospective patient 
disease history data had been entered into their register. We performed the more detailed analysis of register 
data from the following five hospital districts: Helsinki and Uusimaa, Southwest Finland, Tavastia Proper, 
Northern Savonia and Central Finland (Figure 2 dark blue regions). In Table 2 we present the demographics and 
disease characteristics of MS patients from the five hospital districts. In this data-set there were 5365 MS 
patients, 66.7% had RRMS, 13.5% SPMS and 7.9% PPMS. A total of 5.7% of the RRMS patients were 
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classified as having a highly active MS defined by at least two relapses during the previous year or at least one 
relapse during the previous year in spite of DMT treatment. A total of 66.0% of RRMS patients were currently 
receiving a DMT, and 16.6% of the RRMS patients were treated with fingolimod, cladribine, natalizumab, 
ocrelizumab, rituximab, mitoxantrone or alemtuzumab, which were considered as escalation treatments or 
treatment choices for highly active MS according to the national MS treatment guidelines (16). A total of 6.7% 
of the patients were receiving infusion therapies as the first line treatment. The most used DMT options in the 
PPMS patients were rituximab and azathioprine (data not shown). 
 
The mean age of a patient with RRMS in the five hospitals cohort of MS patients was 48.2 years and in patients 
with SPMS 61.7 years (Table 2). The age distribution of the patients is shown in Figure 3A. The age of 52.0 
years, disease duration over 16.5 years and EDSS 3.5 seemed to determine a cut-off point between RRMS and 
SPMS disease stages (Figure 3A, 3B and 3C). 
 
Discussion 
A key feature of the Finnish MS register is the possibility for integration of the register core variables directly 
into the electronic patient documentation system of each participating hospital. This enables automated transfer 
of new MS diagnoses and all other integrated register variables into the register as well as automated updates of 
the deceased patients. In Finland, MS is exclusively diagnosed and mostly treated by neurologists working in 
public health care. Once the register use and the diagnosis integrations cover all the public hospitals, the register 
can provide a full coverage and a constant update on the national incidence and prevalence of MS. The Finnish 
MS register coverage for the core variables of patient demographics and date/year of diagnosis has risen to 
cover approximately 80% of the MS patients within 5 years after its launch. Both retrospective and prospective 
disease history information is currently available from approximately half of the patients, but it has to be taken 
into consideration that the retrospective disease history data has been entered in some hospitals also by medical 
students and MS nurses and not solely by the treating neurologists. This could influence the reliability of the 
retrospective data. 
 
Based on published regional figures from 1990’s, estimates of the prevalence of MS in Finland have been 
approximately 7000 in a population of 5.5 million (17, 18). The numbers of MS patients alive with 
reimbursement rights for DMTs of MS (Social Insurance Institution of Finland, insurance code 109 for G35) 
was 9027 by the end of 2017 and 9372 at 31.12.2018 (11). Since all patients do not apply for the reimbursement 
rights for the DMTs, this figure does not capture all of the Finnish MS patients. In our recent paper investigating 
the prevalence of MS in Southwest Finland and North Carelia hospital districts, we showed standardized 
prevalence figures of 280 and 168 per 100 000, respectively, in the age group over 10 years (4.9 of the 5.5 
million inhabitants). This suggests a longitudinal gradient and yields a combined prevalence of 247/100 000, 
which would give a total number of approx. 13 500 patients applied to the total population. Previously, a much 
smaller crude prevalence of 103/ 100 000 in Northern Finland has been published (19) suggesting a latitudinal 
gradient and supporting a smaller national prevalence than estimated by the combined prevalence of Western 
and Eastern Finland. There were large regional differences in the estimated prevalence in our study consistent 
with the previously published data, but due to different ways of data capture between hospital districts 
(administrational data vs register data), firm conclusions of longitudinal and latitudinal prevalence gradients in 
our country remain to be established in further studies.  
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Based on this and the data presented in the current paper, we estimate that the number of MS patients in our 
country is between 10 and 11 000 patients in a population of 5.5 million. Some of the registered 512 patients 
with G37.9 diagnosis (mostly clinically isolated syndrome, CIS) could possibly fulfill the 2017 McDonald 
diagnostic criteria for MS if they were re-evaluated, but their number is small and does not materially change 
our estimate of MS prevalence in Finland at the end of year 2018. The rise in the MS prevalence in our country 
reflects the globally acknowledged increasing trend of MS prevalence, attributed to more sensitive diagnostics, 
improved prognosis and increasing female to male-ratio with higher life expectancy in females (20, 21). The 
female-to-male ratio in our national registry cohort was 2.5 at 31.12.2018, while ratios ranging from 1.6 to 2.4 
in different regions in Finland have been published from a period spanning from 1979 to 1993 (18). A more 
striking increase has occurred in the mean age of the patients from 38.2 years between years 1979 to 1993 (18) 
to 51 years in the current registry cohort. This suggests that aging of the population and improved survival has a 
more pronounced role in the increasing prevalence than a changing gender ratio.    
 
The natural tendency of RRMS to transform into SPMS in patients without DMTs used is considerable. In older 
studies, 58.2% reach SPMS within a median of 18.9 years (22). In a more recent study from the treatment era, 
only 18.1% of RRMS patients confronted this conversion after a median of 16.8 years (23). Our data contain 
both patients diagnosed before and after the DMT era with varying treatment histories, and therefore straight 
comparisons to either of these results cannot be made. In the light of EDSS accumulation, it has been reported 
that after EDSS 3 there is a tendency of both treated and treatment-naive MS to transform into SPMS, and 
present thereafter with steady incline in disability (24). The EDSS distributions of our RRMS and SPMS patient 
cohorts are in line with this finding, because after reaching EDSS 3.5 the proportion of RRMS patients sharply 
declined (Figure 3).   
 
The proportion of Finnish RRMS patients currently treated with DMT’s was 66.0%, which is similar to that 
previously reported from Sweden (25). The proportion of SPMS patients is likely to be underreported and may 
reflect the reluctance of clinicians to identify the patients as having secondary progressive MS because of 
lacking effective DMT options for this disease phase. The proportion of SPMS patients treated with DMTs was 
19.6% in our analysis. Additionally, 9.9% of the patients with PPMS were also receiving DMTs although the 
first DMT licensed to PPMS did not become available in Finland until February 2018.  
 
There is a subgroup of RRMS patients who have a more aggressive disease course called highly active MS that 
has been estimated to comprise about 4-15% of the patients (26). There is no consensus criteria or treatment 
algorithms for these patients, but MRI lesions that enhance Gadolinium despite treatment, an EDSS scale of 4 
points at 5 years of onset of the disease, no response to treatment with one or more DMTs for at least one year 
and multiple relapses (two or more) with incomplete recovery in the ongoing year, belong to the criteria. Our 
data from the five hospital districts showed a prevalence of 5.7% of MS patients with highly active disease 
defined by at least two relapses during the previous year or at least one relapse during the previous year in spite 
of DMT treatment. Adding the MRI and EDSS criteria will allow better identification of these patients in the 
future. 
 
Now five years after its launch, the Finnish MS register serves the majority of Finnish neurologists taking care 
of MS patients and is increasingly adopted as a part of clinical practice. It has clear benefits regarding the 
concise presentation of all clinical data for an MS patient, allowing the clinician to easily get an overview of the 
patient’s disease course and medications instead of browsing through a large quantity of medical records. 
Therefore, it is easier to make quicker data-based treatment decisions during the patient visit. The graphic view 
of the course of the disease can be shown to the patient at the visit, enabling the patient to take part in the 
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decision making when for instance initiating or changing the treatment. It also helps the patients to understand 
the grounds for determining the type of the disease and disease activity. MS register is an excellent means to 
empower patients to take charge of their disease and commit to the treatment, rehabilitation and beneficial life 
style choices. Also, during the partially virtual expert consultations for more challenging patients, all 
participants get a quick digital picture of the patient history, based on which to make treatment decisions. 
 
The challenges lie in broadening the scope of data entries to include also e.g. MRI results, and to ensure the 
comprehensive longitudinal data collection of existing variables. Changes in electronic patient medical record 
systems require constant updates of the integrations. Use of the register is not compulsory and funding is based 
on the decision of each hospital district to include the register fees into their tightening budgets. Funding has 
raised concern also in other European countries (5), and MS registers need to continuously prove their benefits.  
 
As the register becomes more detailed and covers all MS patients, research questions regarding both MS 
epidemiology and real-world data can be more efficiently addressed. Subgroups such as patients with highly 
active MS can be identified from the MS register, facilitating targeted patient recruitment for clinical trials or 
other research purposes. Genome-wide single nucleotide polymorphism data is generated in Finland through the 
national Finngen project (finngen.fi) from samples donated to biobanks, covering whole Finland (finbb.fi). The 
genetic data is made available for researchers and these data in combination with the Finnish MS register’s 
clinical information make efficient pharmacogenomic analyses possible on a nation-wide scale. Moreover, 
associations of many clinical parameters (e.g. disease course, prognosis, co-morbidity) with genetic markers can 
be tested in an efficient manner and eventually it will be possible to recruit patients to clinical trials on the basis 
of demographic, clinical and genetic variables. 
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Table 1. Variables included in the Finnish MS register and their data counts 
 
Data sections  Data counts  % patients with data 
Demographics (mandatory)     
Name and identification number  9234 9234 (100.0) 
Date of birth  9234 9234 (100.0) 
Gender  9234 9234 (100.0) 
Municipality  8315 8315 (90.0) 
Diagnosis (mandatory)     
Date/year of onset of symptoms  5038 5038 (54.6) 
Date/year of diagnosis  8722 8722 (94.5) 
Diagnosis type (G35,G37.9, conversion to SPMS)*  11574 9234 (100.0) 
Clinical course (RRMS, SPMS, PPMS) 6720 5865 (63.5) 
Anatomical localization(s) of initial symptoms  1251 1251 (13.5) 
MRI at diagnosis (optional)  1008 990 (10.7) 
CSF-analyses at diagnosis (optional)  791 775 (8.4) 
Disease modifying treatment (mandatory)     
Treatment history (start and end dates)  7725 3658 (39.6) 
Current treatment (start date of current treatment)  3979 3979 (43.1) 
Adverse events  2275 1448 (15.7) 
Reasons for treatment discontinuation 7230 3559 (38.5) 
Relapses     
Date  19585 5812 (62.9) 
Symptoms  18668 5690 (61.6) 
Corticosteroid treatment (mandatory)  13419 4421 (47.9) 
EDSS score (mandatory)     
Scores  14530 4035 (43.7) 
MRI (optional)     
Date  13489 4588 (49.7) 
Total number of T2 lesions (semiquantitative) 3199 1506 (16.3) 
Number of new lesions or arrow indicating increased  1549 1001 (10.8) 
lesion load     
Gadolinium use  8338 3569 (38.7) 
Symbol Digit Modalities Test result [SDMT (12)]     
Scores 373 127 (1.4) 
Lab test results     
CSF analysis of cells and IgG production  2967 2620 (28.4) 
Blood biomarkers:     
JCV serology  705 431 (4.7) 
Serum 25-D concentration  2664 1632 (17.7) 
Patient reported outcome measure MyMS (optional)     
Number of patients registered 477 477 (5.2) 
Multiple Sclerosis Impact Scale [MSIS-29 (13)]  213 197 (2.1) 
Quality of life 15D (14)  138 129 (1.4) 
Fatigue severity scale [FSS (15)]  293 252 (2.7) 
Comorbidities 981 763 (8.3) 
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Smoking 1126 1022 (11.1) 
Education 574 519 (5.6) 
Employment 1083 956 (10.4) 
Family history of MS 170 160 (1.7) 
Footnote to Table 1: 8722 MS (G35) and 512 unspecified demyelinative disease of the central 
nervous system (G37.9) patients (total of 9234) were registered at 31.12.2018. There can be 
multiple entries of data for each data section and therefore the data counts differ from the number 
of patients. Diagnosis type data count exceeds the total number of patients because conversion to 
SPMS is entered as a new diagnosis. 
 
 
Table 2. Demographics and disease characteristics of MS patients from the five hospital districts 
Diagnosis Number of patients (%) Age (Years; Mean, SD) Gender  (% F/M) 
G35  5365 (95.0%)                                           51.7 (14.1) 72.4/ 27.6 
G37.9 284 (5.0%) 47.3 (13.0) 71.5/ 28.5 
All  5649 (100.0%) 51.3  (13.6) 72.4/ 27.7 
Disease type Number of patients (%) Age (Years; Mean, SD) Gender  (% F/M) 
RRMS  3578 (66.7%) 48.2 (12.6) 74.5/ 25.5 
SPMS  723 (13.5%) 61.7 (10.4) 69.0/ 31.0 
PPMS  425 (7.9%) 62.3 (10.2) 62.1/ 37.9 
Highly active 
disease 
Number of patients (%) Age (Years; Mean, SD) Gender  (% F/M) 
RRMS 195 (5.7%) 43.4 (10.3) 75.4/ 24.6 
SPMS 17 (2.4 %) 57.9 (10.0) 76.5/ 23.5 
Number of 
patients with 
DMTs (%) 
Any DMT 
IFN, GA, DMF or 
TRF 
Fingolimod, 
cladribine or 
infusion therapies 
All 2730/ 5365 (50.9%) 1974/ 5365 (36.8%) 756/ 5365 (14.1%) 
RRMS 2363/ 3578 (66.0%) 1769/ 3578 (49.4%) 594/ 3578 (16.6%) 
SPMS 142/ 723 (19.6%) 58/ 723 (8.0%) 84/ 723 (11.6%) 
PPMS 42/ 425 (9.9%) 3/ 425 (0.7%) 39/ 425 (9.2%) 
Footnote to Table 2: MS multiple sclerosis; CIS clinically isolated syndrome; RRMS relapsing remitting MS; 
SPMS secondary progressive MS; PPMS primary progressive MS; EDSS expanded disability status scale; F 
female; M male. SPMS was defined as diagnosed by the treating neurologist. Highly active disease was defined 
by at least 2 relapses during the previous year or at least one relapse during the previous year in spite of DMT 
treatment. IFN (Interferon beta), GA (Glatiramer acetate), DMF (Dimethyl fumarate) and TRF (Teriflunomide). 
Infusion therapies include Natalizumab, Alemtuzumab, Ocrelizumab, Mitoxantrone and Rituximab. 
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Figure legends 
Figure 1. The user interface of the Finnish MS register. First page of the user interface of the Finnish MS 
register gives an overview of the individual clinical history: MS diagnosis date (green dots), the diagnostic 
criteria used and the disease type (CIS, RRMS, SPMS or PPMS); disease modifying therapies (coloured bars); 
relapses (brown dots); methylprednisolone pulse therapies (violet dots); expanded disability status (EDSS) 
scores (blue dots and line); brain and spinal cord magnetic resonance imaging (MRI) dates, total number and 
location of lesions, numbers of new lesions and Gadolinium enhancing lesions; laboratory test results. The 
interface includes a fully automated EDSS calculator for EDSS estimation. Entering MRI data is optional. 
Laboratory values are obtained in most hospitals automatically by integration of the hospital laboratory database 
into the register.    
 
Figure 2. Geographical presentation of MS register coverage in the Finnish health care districts. The 
Finnish health care districts are listed in order of population size, and the number of MS patients in the register 
in each district is given (10). In the map, the health care districts who have not yet joined the register are 
coloured grey, and the patient numbers retrieved from their discharge data are shown in the Table. The five 
hospital districts coloured in dark blue are analyzed in detail in this study. The health care districts using 
diagnosis (dg) integration and thence with coverage of all the MS patients in the administrative hospital 
discharge data also in the register, are shown. The number of MS patients in these hospital districts represents a 
crude MS prevalence at 31.12.2018 in these areas. Discharge data gave altogether 778 patients, and with the 
8722 patients listed in the register, we reach a total of 9500 MS patients. 
 
Figure 3. The age (A), time since diagnosis (B) and EDSS distribution (C) of the RRMS and SPMS 
patients registered in the five hospital districts with retrospective data. The five hospital districts were 
Helsinki and Uusimaa, Southwest Finland, Northern Savonia, Tavastia Proper, and Central Finland. There were 
a total of 4642 RRMS patients and 723 SPMS patients available in the register for this analysis. RR refers to 
RRMS and SP to SPMS. Density on the y axis refers to probability for x-axis values. SPMS was defined as 
diagnosed by the treating neurologist.  
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